At-home chemotherapy for HR+ breast cancer works best when pharmacists guide oral regimens, boosting adherence, safety, and affordable access.
Publication|Articles|October 16, 2025
Pharmacy Practice in Focus: Oncology
- October 2025
- Volume 7
- Issue 7
Current and Emerging BCMAxCD3 Bispecifics
Author(s)Rebekah R. Dyer, PharmD, BCPS
Advertisement
Advertisement
In the past 10 years, bispecific antibodies have revolutionized the treatment algorithm for relapsed or refractory multiple myeloma. To date, there are 3 BCMA-directed bispecific antibodies that treat RRMM: teclistamab, elranatamab, and linvoseltamab. Therapy sequence and distinctions among agents are a current clinical conundrum. Ongoing research focuses on drug differences, order of agents, managing resistance, and mitigating adverse effects to improve outcomes in multiple myeloma.
Related to this article
Pharmacy teams can prevent early discontinuation by setting clear expectations for when—and how—a medication's benefit will become apparent.
Pharmacists make a difference in patients’ lives through MTM services.
Peptide cancer vaccines target neoantigens to boost T cells, with promising melanoma and pancreatic trials hinting at a new era in immunotherapy.
Each October, the pharmacy profession pauses to recognize technicians' decades-long evolution, from on-the-job trainees to nationally certified health care professionals.
Peer Reviewed
Creating institution-specific, literacy-friendly chemotherapy education sheets resulted in patient education materials with higher readability scores than similar materials from common chemotherapy education sites.
How oncology pharmacy leaders fight burnout with stay surveys, smarter schedules, and recognition—building resilient teams through loss and turnover.
Managing medication safety in specialized populations requires a shift from standardized dosing to precise, patient-specific customization.
Advertisement
Advertisement